Mizuho Securities Keeps Their Buy Rating on Assembly Biosciences (ASMB)Tip Ranks·Jun 12 at 02:15 PMASMB+0.36%
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline ExpandsMarket Beat·Jun 5 at 02:03 PMASMB+0.36%GIS
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSCTradingView·May 23 at 02:13 AMASMB+0.36%
Assembly Biosciences Prices 3.35 Mln Shares At $26.50/shr; To Expand ABI-6250 Development; Stock Uprttnews·May 22 at 07:44 AMASMB+0.36%
Assembly Bio to expand ABI-6250 into PBC and PSC; Phase 2 HDV trial set for Q4 2026TradingView·May 22 at 06:23 AMASMB+0.36%
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants | ASMB Stock NewsStockTitan·May 21 at 10:05 PMASMB+0.36%
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases | ASMB Stock NewsStockTitan·May 21 at 10:00 PMASMB+0.36%
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA ConferenceMarket Beat·May 14 at 06:05 AMASMB+0.36%
Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash RunwayTip Ranks·May 13 at 11:06 AMASMB+0.36%
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 | ASMB Stock NewsStockTitan·May 12 at 05:00 PMASMB+0.36%
Assembly Biosciences GAAP EPS of -$0.54 beats by $0.03, revenue of $8.21M beats by $1.26Mbusinessinsider·May 7 at 04:27 PMASMB+0.36%
